Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Osaka City University | OTHER |
| Yodogawa Christian Hospital | OTHER |
| Kurashiki Central Hospital | OTHER |
| Nagoya University |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a pilot study to test feasibility and safety of intravenous infusion of autologous umbilical cord blood cells in the first 72 hours after birth if a neonate is born with signs of encephalopathy.
This is a multicenter pilot study to evaluate the feasibility and safety of intravenous infusions of autologous (the patient's own) umbilical cord blood cells in term gestation newborns with neonatal encephalopathy (hypoxic-ischemic encephalopathy). If a neonate is born with signs of moderate to severe encephalopathy and cooled for the encephalopathy, the neonate can receive their own non-cryopreserved volume- and red blood cell-reduced cord blood cells. The cord blood cells are divided into 3 doses and infused at 12-24, 36-48, and 60-72 hours after the birth. Infants will be followed for safety and neurodevelopmental outcome up to 18 months.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cell therapy | Experimental | Infants who are born at the study sites, have moderate to severe encephalopathy, and have cord blood available for infusion |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Autologous umbilical cord blood cells | Other | Autologous non-cryopreserved volume- and red blood cell-reduced cord blood cells will be intravenously infused |
|
| Measure | Description | Time Frame |
|---|---|---|
| Adverse event rates | Adverse event rates (combined rate of death, continuous respiratory support, and continuous use of vasopressor) will be compared between the cell recipients and historical controls at 30 days of age. | first 30 postnatal days |
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy | Neuroimaging at 12 months of age and neurodevelopmental function at 18 months of age will be compared between the cell recipients and historical controls. | 18 months |
Not provided
Inclusion Criteria:
Infants are eligible if they meet all the following inclusion criteria except 4.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Haruo Shintaku, MD, PhD | Osaka City University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nagoya University Hospital | Nagoya | Aichi-ken | 466-8560 | Japan | ||
| Kurashiki Central Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24444827 | Background | Tsuji M, Taguchi A, Ohshima M, Kasahara Y, Sato Y, Tsuda H, Otani K, Yamahara K, Ihara M, Harada-Shiba M, Ikeda T, Matsuyama T. Effects of intravenous administration of umbilical cord blood CD34(+) cells in a mouse model of neonatal stroke. Neuroscience. 2014 Mar 28;263:148-58. doi: 10.1016/j.neuroscience.2014.01.018. Epub 2014 Jan 18. | |
| 25034178 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020925 | Hypoxia-Ischemia, Brain |
| ID | Term |
|---|---|
| D002545 | Brain Ischemia |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| OTHER |
| Osaka City General Hospital | OTHER |
| Saitama Medical University | OTHER |
| National Cerebral and Cardiovascular Center, Japan | OTHER |
| National Center for Child Health and Development, Japan | OTHER |
| Tokyo University | OTHER |
| Tokyo Women's Medical University | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
| Kurashiki |
| Okayama-ken |
| 710-8602 |
| Japan |
| Saitama Medical University | Kawagoe | Saitama | 350-0495 | Japan |
| Yodogawa Christian Hospital | Osaka | 533-0032 | Japan |
| Osaka City General Hospital | Osaka | 534-0021 | Japan |
| Osaka City University | Osaka | 545-8585 | Japan |
| Ohshima M, Taguchi A, Tsuda H, Sato Y, Yamahara K, Harada-Shiba M, Miyazato M, Ikeda T, Iida H, Tsuji M. Intraperitoneal and intravenous deliveries are not comparable in terms of drug efficacy and cell distribution in neonatal mice with hypoxia-ischemia. Brain Dev. 2015 Apr;37(4):376-86. doi: 10.1016/j.braindev.2014.06.010. Epub 2014 Jul 14. |
| 15286799 | Background | Taguchi A, Soma T, Tanaka H, Kanda T, Nishimura H, Yoshikawa H, Tsukamoto Y, Iso H, Fujimori Y, Stern DM, Naritomi H, Matsuyama T. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest. 2004 Aug;114(3):330-8. doi: 10.1172/JCI20622. |
| D009422 | Nervous System Diseases |
| D002534 | Hypoxia, Brain |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D000860 | Hypoxia |
| D012818 | Signs and Symptoms, Respiratory |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |